#United States #Chicago #Jazz Pharmaceuticals #Epidiolex #Xywav

Introduction

Jazz Pharmaceuticals plc, listed on Nasdaq under the ticker JAZZ, is set to make a remarkable appearance at the 2026 American Academy of Neurology (AAN) Annual Meeting, scheduled from April 18-22, 2026 in Chicago. The company plans to unveil six key abstracts, one of which will be presented orally, emphasizing their dedication to advancing knowledge in the field of rare neurological disorders. This meeting promises to shed light on innovative therapeutic solutions, particularly focusing on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates).

Commitment to Research

The commitment of Jazz Pharmaceuticals to address significant unmet needs in the domain of rare neurological disorders, such as epilepsy and sleep disorders, highlights its ongoing research efforts. Jessa Alexander, Ph.D., the neuroscience therapeutic area head for global medical and scientific affairs at Jazz Pharmaceuticals, expressed pride in the company's participation, noting the importance of understanding the complexities of these disorders. She emphasized the necessity of closing persistent gaps in care through continued research into Epidiolex and Xywav.

Highlights of Presentations

Among the presentations at the event, several key findings will be highlighted:
1. Oral Presentation: A 6-month intermediate analysis from the ongoing EpiCom Phase 3b/4 study is expected to showcase a decrease in the severity of behavior problems reported by caregivers and clinicians. This reduction was measured 26 weeks following the initiation of treatment with Epidiolex in patients experiencing TSC-associated seizures.
2. Poster Presentation: An exploration of sociodemographic and clinical factors influencing adherence to Epidiolex among patients diagnosed with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), Tuberous sclerosis complex (TSC), and other refractory epilepsies. The analysis, based on claims data from over 7,800 patients, aims to identify key factors that may improve treatment continuity in an environment marked by care variability.
3. Narcolepsy Study: Another poster presentation will detail research conducted on adults suffering from narcolepsy. The DUET (Develop hypersomnia Understanding by Evaluating Low-Sodium Oxybate Treatment) study revealed significant improvements in cognitive complaints and daily functioning among participants who increased their Xywav dosage beyond 9 grams per night compared to the standard 9 grams dose.

About Epidiolex and Xywav

Both Epidiolex and Xywav are potent therapeutic options addressing unique aspects of neurological health.

• - Epidiolex, a plant-derived medication, contains purified cannabidiol (CBD) and has been approved for use in the treatment of seizures linked to LGS, DS, and TSC in patients aged one year and older. Regulatory approvals span multiple countries, emphasizing its global relevance.
• - Xywav, on the other hand, is the first low-sodium oxybate approved by the U.S. Food and Drug Administration (FDA) for treating both cataplexy and excessive daytime sleepiness (EDS) in narcoleptic patients aged seven and older. Its formulation offers tremendous benefits, significantly reducing sodium intake compared to traditional therapies, thereby enhancing cardiovascular safety.

Conclusion

As Jazz Pharmaceuticals gears up for the AAN Annual Meeting, the research presented is poised to mark significant advancements in the understanding and treatment of rare neurological disorders. Through the use of Epidiolex and Xywav, the company is committed to improving patient lives and uncovering new avenues for treatment. The meeting will serve as a pivotal platform for sharing groundbreaking findings that may shape the future of neurology. To access the full list of presentations and additional resources, visit the official AAN website: AAN2026.

Jazz Pharmaceuticals’ ongoing research reflects a broader commitment to addressing the challenges faced by patients with rare neurological conditions. Their continued innovation and dedication to advancing therapeutic options will be crucial in bridging the gap in the quality of care that these patients receive.